Terns Capital Stock vs Total Current Assets Analysis
TERN Stock | USD 5.71 0.11 1.96% |
Terns Pharmaceuticals financial indicator trend analysis is much more than just breaking down Terns Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Terns Pharmaceuticals is a good investment. Please check the relationship between Terns Pharmaceuticals Capital Stock and its Total Current Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
Capital Stock vs Total Current Assets
Capital Stock vs Total Current Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Terns Pharmaceuticals Capital Stock account and Total Current Assets. At this time, the significance of the direction appears to have pay attention.
The correlation between Terns Pharmaceuticals' Capital Stock and Total Current Assets is -0.78. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Total Current Assets in the same time period over historical financial statements of Terns Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Terns Pharmaceuticals' Capital Stock and Total Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of Terns Pharmaceuticals are associated (or correlated) with its Total Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Assets has no effect on the direction of Capital Stock i.e., Terns Pharmaceuticals' Capital Stock and Total Current Assets go up and down completely randomly.
Correlation Coefficient | -0.78 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Capital Stock
The total amount of a company's capital funded by shareholders through the issue and subscription of shares.Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Most indicators from Terns Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Terns Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.At this time, Terns Pharmaceuticals' Tax Provision is very stable compared to the past year. As of the 22nd of November 2024, Selling General Administrative is likely to grow to about 41 M, while Issuance Of Capital Stock is likely to drop about 39.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 170K | 2.1M | 12.9M | 13.5M | Net Interest Income | 170K | 2.1M | 12.9M | 13.5M |
Terns Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Terns Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Terns Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 23.9M | 92.3M | 168.1M | 287.0M | 268.5M | 170.3M | |
Other Current Liab | 3.3M | 7.5M | 3.9M | 4.4M | 7.0M | 5.1M | |
Total Current Liabilities | 5.0M | 22.8M | 6.8M | 8.5M | 11.9M | 10.5M | |
Total Stockholder Equity | 4.2M | 68.6M | 160.3M | 276.9M | 255.4M | 153.6M | |
Other Liab | 630K | 877K | 947K | 1.1M | 1.2M | 806.7K | |
Net Tangible Assets | (90.8M) | (117.4M) | 172.2M | 276.9M | 318.5M | 334.4M | |
Property Plant And Equipment Net | 961K | 1.2M | 1.0M | 1.8M | 1.0M | 1.2M | |
Net Debt | (12.3M) | (62.0M) | (47.7M) | (142.0M) | (79.3M) | (83.3M) | |
Retained Earnings | (91.9M) | (131.9M) | (182.1M) | (242.4M) | (332.6M) | (316.0M) | |
Accounts Payable | 1.6M | 935K | 2.1M | 1.6M | 2.5M | 1.8M | |
Cash | 12.3M | 74.9M | 47.7M | 143.2M | 79.9M | 80.8M | |
Non Current Assets Total | 1.7M | 1.4M | 1.1M | 1.8M | 1.1M | 1.4M | |
Non Currrent Assets Other | 719K | 246K | 94K | 37K | 56K | 53.2K | |
Other Assets | 719K | 246K | 94K | 37K | 1.0 | 0.95 | |
Cash And Short Term Investments | 19.7M | 74.9M | 166.0M | 283.1M | 263.4M | 163.9M | |
Common Stock Shares Outstanding | 25.1M | 25.1M | 25.3M | 36.0M | 71.3M | 37.9M | |
Short Term Investments | 7.3M | 0.0 | 118.3M | 139.9M | 183.5M | 192.7M | |
Liabilities And Stockholders Equity | 23.9M | 92.3M | 168.1M | 287.0M | 268.5M | 170.3M | |
Non Current Liabilities Total | 14.7M | 877K | 947K | 1.6M | 1.2M | 1.1M | |
Other Current Assets | 461K | 3.3M | 1.9M | 2.1M | 4.0M | 2.2M | |
Other Stockholder Equity | 1.2M | 14.6M | 342.7M | 520.2M | 588.0M | 617.4M | |
Total Liab | 19.7M | 23.7M | 7.8M | 10.1M | 13.2M | 12.2M | |
Net Invested Capital | (90.8M) | (104.6M) | 160.3M | 276.9M | 255.4M | 268.1M | |
Property Plant And Equipment Gross | 961K | 1.2M | 2.2M | 3.2M | 2.6M | 1.9M | |
Total Current Assets | 22.2M | 90.9M | 166.9M | 285.2M | 267.4M | 168.9M | |
Accumulated Other Comprehensive Income | (106K) | (124K) | (338K) | (822K) | (19K) | (20.0K) | |
Net Working Capital | 17.3M | 68.0M | 160.1M | 276.7M | 255.5M | 158.4M | |
Property Plant Equipment | 961K | 1.2M | 1.0M | 757K | 870.6K | 924K |
Pair Trading with Terns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Terns Stock
Moving against Terns Stock
0.65 | DRUG | Bright Minds Biosciences | PairCorr |
0.51 | SABSW | SAB Biotherapeutics | PairCorr |
0.37 | KTTAW | Pasithea Therapeutics | PairCorr |
0.35 | VERA | Vera Therapeutics | PairCorr |
0.35 | DVAX | Dynavax Technologies | PairCorr |
The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 0.035 | Return On Assets (0.19) | Return On Equity (0.28) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.